Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Telbivudine versus lamivudine in patients with chronic hepatitis B.

The New England journal of medicine - 20 Dec 2007

Lai Ching-Lung, Gane Edward, Liaw Yun-Fan, Hsu Chao-Wei, Thongsawat Satawat, Wang Yuming, Chen Yagang, Heathcote E Jenny, Rasenack Jens, Bzowej Natalie, Naoumov Nikolai V, Di Bisceglie Adrian M, Zeuzem Stefan, Moon Young Myoung, Goodman Zachary, Chao George, Constance Barbara Fielman, Brown Nathaniel A

Abstract excerpt

BACKGROUND: Reducing hepatitis B virus (HBV) replication to minimal levels is emerging as a key therapeutic goal for chronic hepatitis B. METHODS: In this double-blind, phase 3 trial, 1370 patients with chronic hepatitis B were randomly assigned to receive 600 mg of telbivudine or 100 mg of lamiv...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Double-Blind Method
Share to Hepatitis B, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B e Antigens

Share to Hepatitis B Surface Antigens

Share to Lamivudine

Share to Nucleosides

Share to Pyrimidinones

Share to Thymidine

Source

Identifiers

PMID: 18094378
DOI: 10.1056/NEJMoa066422

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18094378-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Telbivudine versus lamivudine in patients with chronic hepatitis B.PMID 18094378Read ↗

Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.Semantic proximity Read ↗

Lamivudine as initial treatment for chronic hepatitis B in the United States.Semantic proximity Read ↗

Long-term outcome of telbivudine versus entecavir in treating higher viral load chronic hepatitis B patients without cirrhosis.Semantic proximity Read ↗

Telbivudine plus adefovir therapy for chronic hepatitis B patients with virological breakthrough or genotypic resistance to telbivudine.Semantic proximity Read ↗

Lamivudine plus adefovir or telbivudine plus adefovir for chronic hepatitis B patients with suboptimal response to adefovir.Semantic proximity Read ↗

Lamivudine for patients with chronic hepatitis B and advanced liver disease.Semantic proximity Read ↗

HBV genotype B/C and response to lamivudine therapy: a systematic review.Semantic proximity Read ↗

Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome.Semantic proximity Read ↗

Chronic hepatitis B: preventing, detecting, and managing viral resistance.Semantic proximity Read ↗

Molecular mechanisms of resistance to antiviral therapy in patients with chronic hepatitis B.Semantic proximity Read ↗

Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4.Semantic proximity Read ↗

Lamivudine monotherapy in chronic hepatitis B patients from the Indian subcontinent: antiviral resistance mutations and predictive factors of treatment response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.